Executives from AbbVie (NYSE:ABBV) outlined upcoming clinical milestones and development priorities across hidradenitis ...

AbbVie (ABBV) stock felt some downward pressure despite reporting better-than-expected fourth-quarter results on Feb. 4.

Vicks took the top spot ahead of Rinvoq, Skyrizi and Tremfya, which continue to be the top spenders on national TV pharma ads.

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...

J&J kicked off the new year with a bang, shelling out more than $78 million to air eight TV ads for Tremfya throughout ...

Any of these three pharmaceutical titans could move the needle in your portfolio.

After acing a study for the induction treatment of ulcerative colitis, AbbVie’s Skyrizi has snatched another win in a maintenance trial. An approval now looks within reach for 2024. Compared with ...

AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...

AbbVie’s ABBV key top-line drivers are its newer immunology medicines, Rinvoq and Skyrizi. Sales of both these drugs have effectively replaced the company’s flagship drug, Humira, which began facing ...

- Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely ...

AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...

- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...